Arbutus to participate at jefferies london healthcare conference

Warminster, pa., nov. 10, 2021 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different modes of action to provide a cure for people with chronic hepatitis b virus (hbv) infection and to treat coronaviruses (including covid-19), today announced that the company will participate in a virtual fireside chat at the jefferies london healthcare conference.
ABUS Ratings Summary
ABUS Quant Ranking